drugset / Trial / NCT04354428

Treatment for COVID-19 in High-Risk Adult Outpatients

NCT04354428

RandomizedParallel-groupDouble-blindTreatment

Summary

This is a randomized trial for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in high-risk adults not requiring hospital admission.The overarching goal of this study is to assess the effectiveness of interventions on the incidence of lower respiratory tract infection (LRTI) progression among high-risk adult outpatients with SARS-CoV-2 infection to inform public health control strategies.

Timeline

Start
2020-04-16
Primary completion
2020-11-03
Completion
2020-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Azithromycin Small molecule 250 mg Oral
Subject Hydroxychloroquine Small molecule 200 mg Oral
Subject Ritonavir Other / unclassified 100 mg Oral
Subject Ritonavir Other / unclassified 400 mg Oral

Indications